Real-time quantitative PCR to detect changes in synovial gene expression in rheumatoid arthritis after corticosteroid treatment

Annals of the Rheumatic Diseases

Volumn 66, Issue 4, 2007, Pages 545-547

  Gerlag, Danielle M ^a   Boyle, David L ^b   Rosengren, Sanna ^b   Nash, Tony ^c   Tak, Paul P ^a   Firestein, Gary S ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1BETA; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MESSENGER RNA; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDNISOLONE; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34147212996     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.059790     Document Type: Article

References (16)

1. Ilyin SE, Belkowski SM, Plata-Salaman CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol 2004;22:411-16.
2. Biomarkers definitions working group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
4. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulpnasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
5. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50:3783-91.
6. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43:1820-30.
7. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, Tak PP. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002;46:2034-8.
8. Dolhain RJ, Ter Haar NT, De Kuiper R, Nieuwenhuis IG, Zwinderman AH, Breedveld FC, et al. Distribution of T cells and signs of T-cell activation in the rheumatoid joint: implications for semiquantitative comparative histology. Br J Rheumatol 1998;37:324-30.
9. Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, Firestein GS. Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res Ther 2003;5:R352-60.
10. Tak PP. Lessons learnt from the synovial tissue response to anti-rheumatic treatment. Rheumatology (Oxford) 2000;39:817-20.
11. Bresnihan B, Tak PP. Synovial tissue analysis in rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999;13:645- 59.
12. Ruderman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravallese EM. Synovial tissue response to treatment with Campath-1H. Arthritis Rheum 1995;38:254-8.
13. Cunnane G, Madigan A, Murphy E, Fitzgerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) 2001;40:62-9.
14. Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble JR, Roberts-Thomson PJ, et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 1997;40:1400-8.
15. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2004;43:2391-6.
16. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:834-8.